Cargando…

Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit

OBJECTIVES: China has a high burden of drug-resistant tuberculosis (TB). As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lin, Chen, Jinou, Innes, Anh L., Li, Ling, Chiang, Chen-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663430/
https://www.ncbi.nlm.nih.gov/pubmed/29088241
http://dx.doi.org/10.1371/journal.pone.0187076
_version_ 1783274810420232192
author Xu, Lin
Chen, Jinou
Innes, Anh L.
Li, Ling
Chiang, Chen-Yuan
author_facet Xu, Lin
Chen, Jinou
Innes, Anh L.
Li, Ling
Chiang, Chen-Yuan
author_sort Xu, Lin
collection PubMed
description OBJECTIVES: China has a high burden of drug-resistant tuberculosis (TB). As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health care facilities in Yunnan. METHODS: We applied multistage cluster sampling using probability proportion to size to select 28 counties in Yunnan. Consecutive pulmonary TB patients were enrolled from either the TB centers of Yunnan Center of Disease Control or designated TB hospitals. Outcomes of interest included the regimen used in the treatment of new and retreatment TB patients; and the proportion of patients treated with adequate dosing of anti-TB drugs. Furthermore, we assess whether there has been reduction in the use of fluoroquinolone and second line injectables in Tuberculosis Clinical Centre (TCC) after the training activity in late 2012. RESULTS: Of 2390 TB patients enrolled, 582 (24.4%) were prescribed second line anti-TB drugs (18.0% in new cases and 60.9% in retreatment cases); 363(15.2%) prescribed a fluoroquinolone. General hospitals (adjusted odds ratio (adjOR) 1.97, 95% confidence interval (CI) 1.47–2.66), retreatment TB cases (adjOR 4.75, 95% CI 3.59–6.27), smear positive cases (adjOR 1.69, 95% CI 1.22–2.33), and extrapulmonary TB (adjOR 2.59, 95% CI 1.66–4.03) were significantly associated with the use of fluoroquinolones. The proportion of patients treated with fluoroquinolones decreased from 41.4% before 2013 to 13.5% after 2013 (adjOR 0.19, 95% CI 0.12–0.28) in TCC. The proportion of patients with correct, under and over dosages of isoniazid was 88.2%, 1.5%, and 10.4%, respectively; of rifampicin was 50.2%, 46.8%, and 2.9%; of pyrazinamide was 67.6%, 31.7% and 0.7%; and of ethambutol was 41.4%, 57.5%, and 1.0%. CONCLUSIONS: The prescribing practice of anti-TB drugs was not standardized, findings with significant programmatic implication.
format Online
Article
Text
id pubmed-5663430
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56634302017-11-09 Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit Xu, Lin Chen, Jinou Innes, Anh L. Li, Ling Chiang, Chen-Yuan PLoS One Research Article OBJECTIVES: China has a high burden of drug-resistant tuberculosis (TB). As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health care facilities in Yunnan. METHODS: We applied multistage cluster sampling using probability proportion to size to select 28 counties in Yunnan. Consecutive pulmonary TB patients were enrolled from either the TB centers of Yunnan Center of Disease Control or designated TB hospitals. Outcomes of interest included the regimen used in the treatment of new and retreatment TB patients; and the proportion of patients treated with adequate dosing of anti-TB drugs. Furthermore, we assess whether there has been reduction in the use of fluoroquinolone and second line injectables in Tuberculosis Clinical Centre (TCC) after the training activity in late 2012. RESULTS: Of 2390 TB patients enrolled, 582 (24.4%) were prescribed second line anti-TB drugs (18.0% in new cases and 60.9% in retreatment cases); 363(15.2%) prescribed a fluoroquinolone. General hospitals (adjusted odds ratio (adjOR) 1.97, 95% confidence interval (CI) 1.47–2.66), retreatment TB cases (adjOR 4.75, 95% CI 3.59–6.27), smear positive cases (adjOR 1.69, 95% CI 1.22–2.33), and extrapulmonary TB (adjOR 2.59, 95% CI 1.66–4.03) were significantly associated with the use of fluoroquinolones. The proportion of patients treated with fluoroquinolones decreased from 41.4% before 2013 to 13.5% after 2013 (adjOR 0.19, 95% CI 0.12–0.28) in TCC. The proportion of patients with correct, under and over dosages of isoniazid was 88.2%, 1.5%, and 10.4%, respectively; of rifampicin was 50.2%, 46.8%, and 2.9%; of pyrazinamide was 67.6%, 31.7% and 0.7%; and of ethambutol was 41.4%, 57.5%, and 1.0%. CONCLUSIONS: The prescribing practice of anti-TB drugs was not standardized, findings with significant programmatic implication. Public Library of Science 2017-10-31 /pmc/articles/PMC5663430/ /pubmed/29088241 http://dx.doi.org/10.1371/journal.pone.0187076 Text en © 2017 Xu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Xu, Lin
Chen, Jinou
Innes, Anh L.
Li, Ling
Chiang, Chen-Yuan
Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit
title Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit
title_full Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit
title_fullStr Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit
title_full_unstemmed Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit
title_short Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit
title_sort prescription practice of anti-tuberculosis drugs in yunnan, china: a clinical audit
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663430/
https://www.ncbi.nlm.nih.gov/pubmed/29088241
http://dx.doi.org/10.1371/journal.pone.0187076
work_keys_str_mv AT xulin prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit
AT chenjinou prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit
AT innesanhl prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit
AT liling prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit
AT chiangchenyuan prescriptionpracticeofantituberculosisdrugsinyunnanchinaaclinicalaudit